Investigational drug · Phase 2
IVIEW-1201
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Fungal Keratitis.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "IVIEW-1201"
First trial start
2027
Dec 1, 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IVIEW-1201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fungal Keratitis
Largest trials
Live from ClinicalTrials.gov: studies naming "IVIEW-1201" as an intervention, largest first.
- Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral ConjunctivitisPivotal-lookingCompleted
IVIEW Therapeutics Inc.Industry
NCT03749317 · 135 participants · Start Feb 20, 2023 · Primary completion Apr 30, 2024
Drug: IVIEW-1201; Placebo · For: Adenoviral Conjunctivitis
Sites: Kolkata, India
- Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial ConjunctivitisPivotal-lookingCompleted
IVIEW Therapeutics Inc.Industry
NCT05816070 · 129 participants · Start Jan 5, 2023 · Primary completion Nov 13, 2023
Drug: IVIEW-1201; Ofloxacin Eye Drops · For: Acute Bacterial Conjunctivitis
Sites: Jinan, China
- Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal KeratitisNot yet recruiting
IVIEW Therapeutics Inc.Industry
NCT06463678 · 60 participants (planned) · Start Dec 1, 2027 · Primary completion Dec 31, 2028
Drug: IVIEW-1201; NATACYN® · For: Fungal Keratitis
Newest research
PubMed records naming it or its code names, newest first.
- In-Vivo Toxicity Studies and In-Vitro Inactivation of SARS-CoV-2 by Povidone-iodine In-situ Gel Forming Formulations.
Liang B, Yuan X, Wei G, et al. · bioRxiv 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.